Clinical Trials in Gardena, California
8 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Metabolic dysfunction-associated steatohepatitis (MASH)
Regeneron Pharmaceuticals120 enrolled71 locationsNCT05519475
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled342 locationsNCT06318169
Recruiting
Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Endometrial Hyperplasia
Bayer207 enrolled86 locationsNCT06904274
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled524 locationsNCT06632444
Recruiting
Phase 2
Study of DONQ52 in Active Celiac Disease
Celiac Disease
Chugai Pharmaceutical92 enrolled38 locationsNCT07239336
Recruiting
Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled917 locationsNCT06283966
Recruiting
Phase 2
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
APOL1-mediated Kidney Disease
AstraZeneca96 enrolled77 locationsNCT06824987
Recruiting
Not Applicable
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Diabetes Mellitus, Type 2DiabetesType 2 Diabetes+2 more
Endogenex, Inc.264 enrolled45 locationsNCT06267391